We are live on !
Find out more
ABS Direct Equity Fund Portfolio holdings
AUM
$159M
Turnover
54.3%
1-Year Est. Return
34.17%
This Fund
S&P 500
This Quarter Est. Return
+29%
1 Year Est. Return
+34.17%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$159M
AUM Growth
+$28.3M
(+22%)
Cap. Flow
-$23.9M
Cap. Flow % of AUM
Cap. Flow %
-15.02%
Top 10 Holdings %
Top 10 Hldgs %
40.37%
Holding
151
New
42
Increased
21
Reduced
43
Closed
40
Avg Time Held
0.4
years
Top 10 Avg Time Held
0.8
years
Top 20 Avg Time Held
0.8
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Galicia Financial Group
GGAL
|
+$3.19M |
| 2 |
Telecom Argentina
TEO
|
+$2.94M |
| 3 |
Sempra
SRE
|
+$2.33M |
| 4 |
Banco Macro
BMA
|
+$2.01M |
| 5 |
Stride
LRN
|
+$1.84M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
StoneCo
STNE
|
+$5.76M |
| 2 |
Inter&Co
INTR
|
+$4.2M |
| 3 |
Nu Holdings
NU
|
+$3.51M |
| 4 |
Cellebrite
CLBT
|
+$3.44M |
| 5 |
XP
XP
|
+$2.46M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.32% |
| 2 | Consumer Discretionary | 16.86% |
| 3 | Industrials | 16.03% |
| 4 | Materials | 6.4% |
| 5 | Financials | 5.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
101
Axsome Therapeutics
AXSM
$7.59B
| $171K | 0.11% |
+245
| New | +$53.1K |
2026 Q2
0 quarters
|
|
102
Stryker
SYK
$119B
| $164K | 0.1% |
315
-205
| -39% | -$64.6K |
2026 Q1
1 quarter
|
|
103
GE HealthCare
GEHC
$37B
| $154K | 0.1% |
64
-2,336
| -97% | -$154K |
2026 Q1
1 quarter
|
|
104
Supernus, Inc. Common Stock
SUPN
$6.07B
| $140K | 0.09% |
+41
| New | +$1.49K |
2026 Q2
0 quarters
|
|
105
Tango Therapeutics
TNGX
$4.21B
| $134K | 0.08% |
+31
| New | +$766 |
2026 Q2
0 quarters
|
|
106
Rein Therapeutics
RNTX
$48.3M
| $130K | 0.08% |
125,000
| – | – |
2025 Q4
2 quarters
|
|
107
Thermo Fisher Scientific
TMO
$259B
| $120K | 0.08% |
+501
| New | +$241K |
2026 Q2
0 quarters
|
|
108
Actuate Therapeutics
ACTU
$7.11M
| $112K | 0.07% |
73,186
+23,186
| +46% | +$53.7K |
2025 Q4
2 quarters
|
|
109
Xcel Energy
XEL
$52.3B
| $96.4K | 0.06% |
+80
| New | +$6.39K |
2026 Q2
0 quarters
|
|
110
S&P Global
SPGI
$136B
| $65.2K | 0.04% |
+407
| New | +$172K |
2026 Q2
0 quarters
|
|
111
Royal Gold
RGLD
$21.6B
| $49.9K | 0.03% |
250
-200
| -44% | -$46.5K |
2025 Q4
2 quarters
|
|
112
Alkermes
ALKS
$7.89B
| – | – |
-4,900
| Closed | -$167K | – |
|
113
Alta Equipment Group
ALTG
$186M
| – | – |
-97,425
| Closed | -$523K | – |
|
114
Arcos Dorados Holdings
ARCO
$1.47B
| – | – |
-109,882
| Closed | -$907K | – |
|
115
Avantor
AVTR
$10.6B
| – | – |
-75,000
| Closed | -$588K | – |
|
116
Axon Enterprise
AXON
$25B
| – | – |
-760
| Closed | -$299K | – |
|
117
Credicorp
BAP
$29B
| – | – |
-4,500
| Closed | -$1.53M | – |
|
118
BridgeBio Pharma
BBIO
$15.2B
| – | – |
-1,243
| Closed | -$85.8K | – |
|
119
Constellation Energy
CEG
$99.3B
| – | – |
-1,160
| Closed | -$372K | – |
|
120
Celcuity
CELC
$3.14B
| – | – |
-1,500
| Closed | -$217K | – |
|
121
Celsius Holdings
CELH
$7.99B
| – | – |
-25,000
| Closed | -$887K | – |
|
122
CG Oncology
CGON
$6.27B
| – | – |
-2,600
| Closed | -$176K | – |
|
|
123
Cellebrite
CLBT
$2.74B
| – | – |
-250,000
| Closed | -$3.44M | – |
|
124
Credo Technology Group
CRDO
$26.3B
| – | – |
-1,100
| Closed | -$198K | – |
|
125
DexCom
DXCM
$30.4B
| – | – |
-2,500
| Closed | -$150K | – |
|
Similar funds
JAIC
ABS Direct Equity Fund's Q2 2026 Portfolio in Review
As of Q2 2026, ABS Direct Equity Fund held 151 positions worth $159M, up 22% from $131M the previous quarter. Its ten largest holdings account for 40% of the portfolio.
ABS Direct Equity Fund withdrew a net $23.9M in Q2 2026, closing 40 positions and reducing 43 holdings. Its most notable exit was StoneCo, an estimated $5.76M position sold in full.
By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 27% a quarter earlier, followed by Consumer Discretionary and Industrials.
Against the trend, ABS Direct Equity Fund opened a new position in Galicia Financial Group worth $3.39M.
- ABS Direct Equity Fund's largest Q2 2026 buy was Galicia Financial Group: 67,845 shares worth $3.39M.
- ABS Direct Equity Fund added most to Sempra in Q2 2026, an estimated $2.33M increase.
- ABS Direct Equity Fund's biggest Q2 2026 reduction was Euronet Worldwide, cutting an estimated $2.09M.
- ABS Direct Equity Fund fully exited StoneCo in Q2 2026, selling an estimated $5.76M.
- ABS Direct Equity Fund's ten largest holdings make up 40% of its $159M portfolio in Q2 2026.
- ABS Direct Equity Fund opened 42 new positions and closed 40 in Q2 2026.
- ABS Direct Equity Fund's portfolio value rose 22% quarter-over-quarter to $159M.
Based on ABS Direct Equity Fund's 13F filing for Q2 2026, filed 13 Aug 2026.